Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes.

Lee EY, Kim SS, Lee JS, Kim IJ, Song SH, Cha SK, Park KS, Kang JS, Chung CH.

PLoS One. 2014 Aug 1;9(8):e102984. doi: 10.1371/journal.pone.0102984. eCollection 2014.

2.

Decreased plasma α-Klotho predict progression of nephropathy with type 2 diabetic patients.

Kim SS, Song SH, Kim IJ, Lee EY, Lee SM, Chung CH, Kwak IS, Lee EK, Kim YK.

J Diabetes Complications. 2016 Jul;30(5):887-92. doi: 10.1016/j.jdiacomp.2016.03.006. Epub 2016 Mar 11.

PMID:
27037042
3.

The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin.

Wu C, Wang Q, Lv C, Qin N, Lei S, Yuan Q, Wang G.

Diabetes Res Clin Pract. 2014 Nov;106(2):343-50. doi: 10.1016/j.diabres.2014.08.026. Epub 2014 Sep 16.

PMID:
25263500
4.

Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A.

Kacso IM, Bondor CI, Kacso G.

Clin Biochem. 2012 Nov;45(16-17):1415-20. doi: 10.1016/j.clinbiochem.2012.07.098. Epub 2012 Jul 23.

PMID:
22836100
5.

Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus.

Nie F, Wu D, Du H, Yang X, Yang M, Pang X, Xu Y.

J Diabetes Complications. 2017 Mar;31(3):594-598. doi: 10.1016/j.jdiacomp.2016.11.008. Epub 2016 Nov 12.

PMID:
27916483
6.

Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.

Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1899-905. doi: 10.2215/CJN.02700313. Epub 2013 Aug 8.

7.

Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria.

Inci A, Sari F, Coban M, Olmaz R, Dolu S, Sarıkaya M, Yılmaz N.

J Investig Med. 2016 Aug;64(6):1128-33. doi: 10.1136/jim-2016-000142. Epub 2016 Jun 20.

PMID:
27323770
8.

Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.

Satirapoj B, Tassanasorn S, Charoenpitakchai M, Supasyndh O.

PLoS One. 2015 Apr 17;10(4):e0124055. doi: 10.1371/journal.pone.0124055. eCollection 2015.

9.

Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy.

van Ark J, Hammes HP, van Dijk MC, Lexis CP, van der Horst IC, Zeebregts CJ, Vervloet MG, Wolffenbuttel BH, van Goor H, Hillebrands JL.

Cardiovasc Diabetol. 2013 Aug 14;12:116. doi: 10.1186/1475-2840-12-116. Erratum in: Cardiovasc Diabetol. 2013;12:120. Lexis, Chris P H [added]; van der Horst, Iwan C C [added]; Zeebregts, Clark J [added].

10.

Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.

Li Z, Xu Y, Liu X, Nie Y, Zhao Z.

Nephrology (Carlton). 2017 Jan;22(1):58-64. doi: 10.1111/nep.12719.

PMID:
26733347
11.

Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy.

Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T.

Metabolism. 2003 May;52(5):605-8.

PMID:
12759891
12.

Adipokine zinc-alpha-2-glycoprotein as a novel urinary biomarker presents earlier than microalbuminuria in diabetic nephropathy.

Wang Y, Li YM, Zhang S, Zhao JY, Liu CY.

J Int Med Res. 2016 Apr;44(2):278-86. doi: 10.1177/0300060515601699. Epub 2016 Feb 8.

13.

Association of plasma soluble α-klotho with pro-endothelin-1 in patients with type 2 diabetes.

Liu JJ, Liu S, Morgenthaler NG, Wong MD, Tavintharan S, Sum CF, Lim SC.

Atherosclerosis. 2014 Apr;233(2):415-8. doi: 10.1016/j.atherosclerosis.2014.01.024. Epub 2014 Jan 22.

PMID:
24530772
14.

TNF-α and microalbuminuria in patients with type 2 diabetes mellitus.

Lampropoulou IT, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadis G.

J Diabetes Res. 2014;2014:394206. doi: 10.1155/2014/394206. Epub 2014 Dec 22.

15.

Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy.

Shiju TM, Mohan V, Balasubramanyam M, Viswanathan P.

J Diabetes Complications. 2015 Apr;29(3):400-6. doi: 10.1016/j.jdiacomp.2014.12.012. Epub 2014 Dec 31.

PMID:
25619588
16.

Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.

Shoukry A, Bdeer Sel-A, El-Sokkary RH.

Mol Cell Biochem. 2015 Oct;408(1-2):25-35. doi: 10.1007/s11010-015-2479-y. Epub 2015 Jun 24.

PMID:
26104579
17.

Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis.

Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX, Zhao HL.

Medicine (Baltimore). 2017 Apr;96(15):e6583. doi: 10.1097/MD.0000000000006583. Review.

18.

Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.

Turk N, Mornar A, Mrzljak V, Turk Z.

Diabetes Metab. 2004 Apr;30(2):187-92.

PMID:
15223992
19.

Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients.

Lim SC, Liu JJ, Subramaniam T, Sum CF.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):487-90. doi: 10.1177/1470320313475905. Epub 2013 Feb 4.

PMID:
23380567
20.

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, Kim BH, Lee SH, Kim YK, Kim IJ.

J Korean Med Sci. 2011 Feb;26(2):258-63. doi: 10.3346/jkms.2011.26.2.258. Epub 2011 Jan 24.

Supplemental Content

Support Center